Method and apparatus for the treatment of movement disorders

• US 8,190,251 B2
• Filed: 11/30/2006
• Issued: 05/29/2012
• Est. Priority Date: 03/24/2006
• Status: Active Grant

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Molnar, Gregory F., Miyazawa, Gabriela C., Miesel, Keith A., Werder, Jonathan C., Carlson, David L., Giftakis, Jonathon E.
• Primary Examiner(s): Mallari, Patricia
• Assistant Examiner(s): D'ANGELO, MICHAEL J
• Application Number:
  US11/565,268
• Publication Number:
  US 20070225674A1
• Time in Patent Office: 2,007 Days
• Field of Search: 600544-545, 607 2- 3, 607/48, 607 68- 69
• US Class Current: 600/545
• CPC Class Codes: A61B 5/374 Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• CPC Class Codes: A61B 5/4082 Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
• CPC Class Codes: A61N 1/36003 of motor muscles, e.g. for walking assistance
• CPC Class Codes: A61N 1/36067 Movement disorders, e.g. tremor or Parkinson disease stimulating motor muscle A61N1/36003

Abstract

A method, apparatus, and system for treating patients suffering from movement disorders having the ability to determine one or more biomarkers indicative of a disease state. In some embodiments, the biomarker may be used as a closed-loop feedback signal to control the delivery of therapy (such as electrical stimulation or drug therapy), and which may also be used as an indication of therapy effectiveness. One embodiment uses electrodes placed in the brain to measure EEG or local field potential (LFP) signals, from which the one or more biomarkers may be determined.

Claims

1. A system for treating a neurological movement disorder, the system comprising:

an implantable medical device comprising a housing for a power supply, memory, and electronic circuitry; and

at least one electrode in communication with the device and adapted to acquire a physiological signal from a brain of a patient, the device being adapted to;

acquire the physiological signal from the brain of the patient;

measure a first value from the physiological signal, the first value representative of an amount of oscillatory activity in a first frequency range;

measure a second value from the physiological signal, the second value representative of an amount of oscillatory activity in a second frequency range;

calculate a biomarker from the first and second values; and

use the biomarker to assess the movement disorder, the biomarker being based on a comparison of the first and second values, and the first and second frequency ranges comprising beta and gamma frequency ranges, respectively.

2. The system of claim 1, wherein the device is adapted to calculate the biomarker by at least determining a ratio of the first and second values.

3. The system of claim 1, wherein the device is adapted to deliver treatment to the patient based on the calculated value of the biomarker.

4. The system of claim 3, wherein the device is adapted to deliver treatment to the patient based upon the biomarker exceeding a reference value.

5. The system of claim 3, wherein the treatment comprises at least one of electrical stimulation therapy or drug delivery therapy.

6. The system of claim 3, wherein the device is configured to recalculate the biomarker after delivering the treatment to the patient to provide closed-loop control of the treatment.

7. The system of claim 3, wherein the device is configured to vary the treatment to achieve a biomarker value within a predefined range.

8. The system of claim 1, wherein the first frequency range is about 7 to about 35 Hz, and wherein the second frequency range is greater than about 50 Hz.

9. The system of claim 8, wherein the first frequency range is about 11 to about 30 Hz, and wherein the second frequency range is about 60 to about 300 Hz.

10. The system of claim 1, wherein the device is adapted to compare the biomarker to a reference value to assess the movement disorder.

11. The system of claim 1, wherein the physiological signal comprises at least one of a local field potential signal, an electroencephalogram signal, or an electrocorticogram signal.

12. The system of claim 1, wherein the first and second values are at least partially based on an energy level of the physiological signal within the respective first and second frequency ranges.

13. The system of claim 1, wherein the first and second values are at least partially based on an amplitude of the physiological signal within the respective first and second frequency ranges.

14. The system of claim 1, wherein the first and second values are at least partially based on a frequency of the physiological signal within the respective first and second frequency ranges.

15. The system of claim 1, wherein the device determines at least one of the first or second values representative of an amount of oscillatory activity using an order statistic filter.

16. An implantable medical device (IMD) for treating neurological movement disorders, the device comprising:

one or more electrodes adapted to acquire a physiological signal from a brain of a patient; and

a processing subsystem adapted to determine a first value and a second value from the physiological signal, the first value representative of an amount of oscillatory activity in a first frequency range, the second value representative of an amount of oscillatory activity in a second frequency range, the processing subsystem further adapted to calculate a biomarker as a function of the first and second values, the biomarker providing an assessment of the movement disorder.

17. The IMD of claim 16 further comprising:

a therapy delivery subsystem adapted to deliver therapy to the patient based on the calculated value of the biomarker.

18. The IMD of claim 17, wherein the therapy delivery subsystem is adapted to provide electrical stimulation therapy delivery.

19. The IMD of claim 17, wherein the therapy delivery subsystem is adapted to provide drug therapy delivery.

20. The system of claim 17, wherein the processing subsystem is adapted to control the therapy delivery subsystem to deliver therapy to the patient based on the calculated value of the biomarker exceeding a predetermined threshold.

21. The system of claim 17, wherein the processing subsystem is adapted to re-calculate the biomarker in conjunction with delivery of therapy to provide closed-loop control of the therapy.

22. The system of claim 17, wherein the processing subsystem is configured to vary the therapy delivered by the therapy delivery subsystem to achieve a biomarker value within a predefined range.

23. The IMD of claim 16, wherein the processing subsystem is adapted to control therapy delivery to the patient based on the biomarker.

24. The system of claim 16, wherein the first frequency range is about 7 to about 35 Hz, and wherein the second frequency range is greater than about 50 Hz.

25. The system of claim 24, wherein the first frequency range is about 11 to about 30 Hz, and wherein the second frequency range is about 60 to about 300 Hz.

26. The system of claim 16, wherein the first and second values are at least partially based on an energy level of the physiological signal within the respective first and second frequency ranges.

27. The system of claim 16, wherein the first and second values are at least partially based on an amplitude of the physiological signal within the respective first and second frequency ranges.

28. The system of claim 16, wherein the first and second values are at least partially based on a frequency of the physiological signal within the respective first and second frequency ranges.

29. A method of treating a neurological movement disorder, the method comprising:

acquiring, with a medical device, a physiological signal from a brain of a patient;

measuring a first value from the physiological signal, the first value representative of an amount of oscillatory activity in a first frequency range;

measuring a second value from the physiological signal, the second value representative of an amount of oscillatory activity in a second frequency range;

calculating, with a processor, a biomarker as a function of the first and second values; and

using the biomarker to assess the movement disorder, the biomarker being based on a comparison of the first and second values, and the first and second frequency ranges comprising beta and gamma frequency ranges, respectively.

30. The method of claim 29, wherein the first frequency range is from about 7 to 35 Hz, and wherein the second frequency range is greater than about 50 Hz.

31. The method of claim 30, wherein the first frequency range is from about 11 to 30 Hz, and wherein the second frequency range is between about 60 and 300 Hz.

32. The method of claim 29, wherein calculating the biomarker includes determining a ratio from the first and second values.

33. The method of claim 29, wherein the physiological signal comprises at least one of a local field potential (LFP) signal, an electroencephalogram (EEG) signal, or an electrocorticogram (ECoG) signal acquired by one or more deep brain stimulation (DBS) electrodes located in the brain of the patient.

34. The method of claim 29, wherein the first and second values representative of an amount of oscillatory activity are at least partially based on an energy level of the physiological signal within the respective first and second frequency ranges.

35. The method of claim 29, wherein the first and second values representative of an amount of oscillatory activity are at least partially based on an amplitude of the physiological signal within the respective first and second frequency ranges.

36. The method of claim 29, wherein the first and second values representative of an amount of oscillatory activity are at least partially based on a frequency of the physiological signal within the respective first and second frequency ranges.

37. The method of claim 29, wherein using the biomarker to assess the movement disorder comprises delivering treatment to the patient based on the biomarker.

38. The method of claim 29, wherein delivering treatment to the patient based on the biomarker comprises delivering treatment to the patient based upon the biomarker exceeding a reference value.

39. The method of claim 37, further comprising recalculating the biomarker in conjunction with delivery of treatment to provide closed-loop control of said treatment.

40. The method of claim 39, further comprising varying the treatment to achieve a value of the biomarker within a predefined range.

41. The method of claim 37, wherein delivering treatment to the patient based on the biomarker comprises delivering different treatment in a first region of the brain and a second region of the brain.

42. The method of claim 37, wherein the treatment delivered is varied according to a desired patient outcome.

43. The method of claim 42, wherein the desired patient outcome comprises at least one of improved manual dexterity or a reduction in tremors.

44. The method of claim 29, wherein at least one of the first and second values representative of an amount of oscillatory activity is determined using an order statistic filter.

45. The method of claim 29, further comprising:

measuring a third value from the physiological signal, the third value representative of an amount of oscillatory activity in a third frequency range; and

calculating the biomarker as a function of the first, second, and third values.

46. A non-transitory computer-readable medium programmed with instructions for performing a method of treating a neurological movement disorder, the computer-readable medium comprising instructions that, when executed by a programmable processor, cause the programmable processor to:

acquire a physiological signal from a brain of a patient;

measure a first value from the physiological signal, the first value representative of an amount of oscillatory activity in a first frequency range;

measure a second value from the physiological signal, the second value representative of an amount of oscillatory activity in a second frequency range;

calculate a biomarker from the first and second values; and

use the biomarker to assess the movement disorder, the biomarker being based on a comparison of the first and second values, and the first and second frequency ranges comprising beta and gamma frequency ranges, respectively.

47. The computer-readable medium of claim 46, wherein the instructions cause the programmable processor to calculate the biomarker by at least determining a ratio of the first and second values.

48. The computer-readable medium of claim 46, further comprising instructions that, when executed by the programmable processor, cause the programmable processor to control a medical device to deliver treatment to the patient based on the biomarker.

49. A method of treating a neurological movement disorder, the method comprising:

acquiring, with a medical device, a physiological signal from a brain of a patient;

determining a first value and a second value from the physiological signal, the first value representative of an amount of oscillatory activity in a first frequency range, the second value representative of an amount of oscillatory activity in a second frequency range;

calculating, with a processor, a biomarker as a function of the first value and the second value; and

using the biomarker to assess the movement disorder.

50. The method of claim 49, wherein the first frequency range is from about 0to 50 Hz.

51. The method of claim 49 wherein the first frequency range is from about 50to 1000 Hz.

52. The method of claim 49, wherein using the biomarker to assess the movement disorder comprises delivering treatment to the patient based on the biomarker exceeding a predetermined threshold.

53. The method of claim 52, wherein treatment comprises at least one of electrical stimulation therapy or drug delivery therapy.

54. The method of claim 52, further comprising varying the treatment to achieve a value of the biomarker within a predefined range.